Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
So | Jerry Almonte De Leon: OpenQuantum and Oneness Blockchain AI Lead the Future of Quantum Innovation | 251 | ACCESSWIRE | Introducing Open Quantum by Jerry Almonte De Leon, Founder of OneNess Blockchain AI. Revolutionizing Quantum-AI and Quantum-CryptographyTORONTO, ON / ACCESSWIRE / November 3, 2024 / Jerry Almonte De... ► Artikel lesen | |
19.09. | Pinion Partners: The Oneness Gallery Cancels Toronto Exhibition and Severs Ties with Canadian Agent | 317 | Newsfile | London, United Kingdom--(Newsfile Corp. - September 18, 2024) - The Oneness Gallery, the exclusive representative of acclaimed artist Avidya, announces the cancellation of its planned September exhibition... ► Artikel lesen | |
18.07. | Die Marke LYCRA®, Jeanologia und Global Denim stellen ihr neuestes Projekt auf der Kingpins New York vor: ONENESS, Amerikas for the Amerikas - | 1 | FashionUnited | ||
18.07. | Die Marke LYCRA®, Jeanologia und Global Denim stellen ihr neuestes Projekt auf der Kingpins New York vor: ONENESS, Amerikas for the Amerikas | 1 | FashionUnited |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,200 | +1,23 % | Aixtron, Evotec, HelloFresh, Nel ASA, Schalke 04, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
ADMA BIOLOGICS | 19,120 | 0,00 % | ADMA Biologics, Inc. (NASDAQ:ADMA) Holdings Increased by Roman Butler Fullerton & Co. | ||
DISC MEDICINE | 58,19 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval | Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,52 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
QIAGEN | 40,350 | +0,45 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,820 | 0,00 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
SUMMIT THERAPEUTICS | 19,980 | 0,00 % | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,075 | 0,00 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
ARCELLX | 86,46 | 0,00 % | Arcellx (ACLX) Surged in Q3. Here's Why | ||
BEAM THERAPEUTICS | 24,340 | 0,00 % | Beam Therapeutics Q3 2024 Earnings Preview | ||
DYNE THERAPEUTICS | 28,780 | 0,00 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,620 | 0,00 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
IMMUNOVANT | 29,435 | 0,00 % | Immunovant Inc.: Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting | ||
TARSUS PHARMACEUTICALS | 46,240 | 0,00 % | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 | ||
VIKING THERAPEUTICS | 60,78 | +4,68 % | Novo Nordisk und Eli Lilly aufgepasst: Showdown bei Viking Therapeutics | In der kommenden Handelswoche ist eine hohe Volatilität bei "Adipositas-Aktien" vorprogrammiert. Denn zwischen dem 3. und 6. November steigt die ObesityWeek im texanischen San Antonio. Unter anderem... ► Artikel lesen |